Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 690 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium chloride injection (0.9%) Clear all
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 10, 2026, 11:09 AM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

NCT01545570
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2376497, 0.9% sodium chloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 10, 2026, 11:09 AM EDT
Terminated Phase 1 Interventional

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

NCT03432741
View directory record Official record
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2025 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

NCT06192927
View directory record Official record
Conditions
Tennis Elbow
Interventions
TenoMiR, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Causeway Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Not listed Phase 2 Interventional

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

NCT03840057
View directory record Official record
Conditions
Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions
Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%
Drug
Lead sponsor
Waihong Chung
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 10, 2026, 11:09 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 10, 2026, 11:09 AM EDT
Active, not recruiting Early Phase 1 Interventional

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures

NCT05037812
View directory record Official record
Conditions
Tibial Plateau Fractures
Interventions
Saline injection, Multimodal injections
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccine for HIV

NCT01859325
View directory record Official record
Conditions
HIV, Therapeutic Vaccine
Interventions
rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Results available

CEUS Evaluation of Hypoxic Ischemic Injury

NCT03549520
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population

NCT03198871
View directory record Official record
Conditions
Abdominal Wall Hernia, Pancreatic Diseases, Bowel Disease, Gastric Disease
Interventions
Acetaminophen Injectable Product, Sodium Chloride 0.9%, Intravenous
Drug
Lead sponsor
Kathirvel Subramaniam
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 10, 2026, 11:09 AM EDT
Recruiting Early Phase 1 Interventional

NSAIDs Stent Study

NCT03638999
View directory record Official record
Conditions
Ureteral Stent Placement, Kidney Stone
Interventions
Ketorolac Trometamol 30Mg/1mL Injection, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955
View directory record Official record
Conditions
Hypertension
Interventions
Saline, QCZ484
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
64
States / cities
Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

NCT06347133
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Not applicable Interventional Results available

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 10, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 11:09 AM EDT